Menu Search
Equities

BioLife Solutions Inc

BJX1:DUS

BioLife Solutions Inc

Actions
  • Price (EUR)23.80
  • Today's Change1.80 / 8.18%
  • Shares traded73.00
  • 1 Year change+96.69%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

  • Revenue in USD (TTM)118.41m
  • Net income in USD-26.44m
  • Incorporated1998
  • Employees409.00
  • Location
    BioLife Solutions IncSUITE 310, 3303 MONTE VILLA PARKWAYBOTHELL 98021United StatesUSA
  • Phone+1 (425) 401-1400
  • Fax+1 (425) 402-1433
  • Websitehttps://www.biolifesolutions.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.